KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Interest Expenses (2016 - 2022)

Historic Interest Expenses for Resmed (RMD) over the last 7 years, with Q1 2022 value amounting to $5.5 million.

  • Resmed's Interest Expenses fell 619.96% to $5.5 million in Q1 2022 from the same period last year, while for Dec 2022 it was $5.5 million, marking a year-over-year decrease of 7602.18%. This contributed to the annual value of $24.0 million for FY2021, which is 4058.75% down from last year.
  • Per Resmed's latest filing, its Interest Expenses stood at $5.5 million for Q1 2022, which was down 619.96% from $5.9 million recorded in Q4 2021.
  • Resmed's Interest Expenses' 5-year high stood at $12.5 million during Q2 2019, with a 5-year trough of $3.7 million in Q3 2018.
  • Over the past 5 years, Resmed's median Interest Expenses value was $6.7 million (recorded in 2020), while the average stood at $7.7 million.
  • As far as peak fluctuations go, Resmed's Interest Expenses plummeted by 5236.99% in 2018, and later soared by 19644.01% in 2019.
  • Resmed's Interest Expenses (Quarter) stood at $7.5 million in 2018, then surged by 36.5% to $10.2 million in 2019, then plummeted by 43.33% to $5.8 million in 2020, then rose by 2.69% to $5.9 million in 2021, then decreased by 8.17% to $5.5 million in 2022.
  • Its Interest Expenses stands at $5.5 million for Q1 2022, versus $5.9 million for Q4 2021 and $5.4 million for Q3 2021.